Key points from article :
UK genomics company Broken String Biosciences has raised $15 million to develop a new technology platform to improve the safety of cell and gene therapies.
The company's INDUCE-seq platform uses next generation sequencing to measure and assess off-target gene editing events, which are a major safety concern for these therapies.
The new funding will be used to further develop the INDUCE-seq platform and make it more scalable, as well as to expand the company's team and establish a US office.
INDUCE-seq could help to accelerate the development of new cell and gene therapies by providing researchers with a more efficient and accurate way to assess the safety of their therapies.
Broken String Biosciences is aiming to develop INDUCE-seq into a "Platform as a Service" offering, making it available to other companies and researchers working in the field of cell and gene therapy.
The company's CEO believes that INDUCE-seq has the potential to "become the gold-standard solution for measuring off-target gene editing."
